CytoDyn 10-K: Going Concern Opinion, $42.7M Loss, and $16.5M Dilutive Placement
CYDY sits 25% above its 52-week low of $0.183.
Summary
CytoDyn's annual report reveals a going concern warning, a $42.7 million net loss, and a heavily dilutive $16.5 million private placement concluded in August 2026.
Key Events · Earnings and Guidance · CYDY
-
Going Concern Opinion
Auditor CBIZ CPAs P.C. issued a going concern explanatory paragraph for fiscal 2026, citing substantial doubt about CytoDyn's ability to continue as a going concern.
-
Fiscal 2026 Net Loss
Net loss of $42.7 million for the year ended May 31, 2026, compared to net income of $3.7 million in fiscal 2025, which included a one-time $25.0 million litigation recovery.
-
Liquidity Crunch
Unrestricted cash of $12.2 million as of July 31, 2026, versus $31.0 million in accounts payable and accrued liabilities. The company states it must raise substantial additional financing in the near term.
-
Dilutive Private Placement
Concluded August 28, 2026: 79.0 million units at $0.20889 per unit for $16.5 million in cash. Each unit includes one share and one warrant with a $0.25 exercise price.
Analysis · CYDY · Life Sciences
The auditor's going concern opinion is the headline risk. CytoDyn has $12.2 million in unrestricted cash against $31.0 million in payables and accrued liabilities, and the company states it must raise substantial additional financing in the near term. The August 2026 private placement of 79.0 million units at $0.20889 per unit raised $16.5 million but added roughly 79 million shares plus warrants — highly dilutive at a price near the stock's 52-week low. The class action settlement, if finalized, will add another 49 million shares. The company's accumulated deficit is $930.5 million. This filing materially changes the risk profile for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYDY was trading at $0.23 on OTC in the Life Sciences sector, with a market capitalization of approximately $313.7M. The 52-week trading range was $0.18 to $0.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.